Abstract: The invention relates to a process for the preparation of tablets containing moxifloxacin, comprising the steps of (i) providing moxifloxacin, pharmaceutically acceptable salts, solvates or hydrates thereof, optionally mixed with one or more pharmaceutical excipients; (ii) compacting it into a slug; (iii) granulating the slug; and (iv) compressing the resulting granules into tablets; and also tablets, granules and compacted material containing compacted moxifloxacin.

Abstract: The invention relates to a process for the preparation of tablets containing moxifloxacin, comprising the steps of (i) providing moxifloxacin, pharmaceutically acceptable salts, solvates or hydrates thereof, optionally mixed with one or more pharmaceutical excipients; (ii) compacting it into a slug; (iii) granulating the slug; and (iv) compressing the resulting granules into tablets; and also tablets, granules and compacted material containing compacted moxifloxacin.

Abstract: A pharmaceutically acceptable topical formulation for the treatment and/or prevention of skin ailments, more particularly of fibriotic nature such as fibriotic lesional tissues, contiguous warts, contact dermatitis, and keloids, and to assist the healing of burns after surgery, comprising as active ingredient a substituted pyridone of the formula: n-(R1)-R2-2-(1H)pyridone or a pharmaceutically acceptable salt or ester thereof, where R1 is selected from methyl, ethyl, propyl, carboxyl and a carboxymethyl or carboxyethyl ester group, R2 is selected from phenyl, methylphenyl, ethylphenyl, propylphenyl, and a carboxyphenyl or carboxyethylphenyl ester group, and n is 3, 4 or 5, together with an excipient, characterized in that the excipient comprises, one or more plasticisers, one or more antioxidants, one or more gel-forming agents and sufficient pH adjusting agent to bring the pH of the formulation to a value from 4 to 8. The preferred active ingredient is 5-methyl-1-phenyl-2-(1H)pyridone (Pirfenidone).

Abstract: The invention relates to a pharmaceutically active composition containing a substance which is active against malaria parasites and shows a high level of activity against multiresistant lines of Plasmodium falciparum. The inventive composition is characterized in that it contains the active agent artemisinine and/or a derivative of artemisinine in a carrier material which is inert with the active agent, in a pharmaceutically active quantity and in that the carrier material is essentially free of compounds with a hydrophilic-lipophilic balance between 7 and 9.9.

Abstract: A pharmaceutical pellet formulation having a core containing omeprazole as an active ingredient, and also having an outer, enteric coating encasing the core. Titanium dioxide is added to the core, and optionally, to the enteric coating in order to retard decomposition of the omeprazole resulting from the action of penetrating moisture and solvents, thus greatly improving the storage stability of the omeprazole formulation.